TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Reduction in the Percent Days of Heavy Drinking Days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: test validity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Metabolic symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: SNAP-IV Rating Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall Response Rate
Endpoint domain: Physiological/clinical
Primary endpoint: time to progression of diabetic retinopathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ophthalmic outcomes
Primary endpoint: Percentage of Participants Achieving Seroprotection Against Influenza Antigens
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Participants Achieving Seroconversion or Significant Increase Against Influenza Antigens
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Postoperative pain during 2 weeks post-treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Safety and Tolerability Profile
Endpoint domain: Adverse events/effects
Primary endpoint: Intraoperative cost of surgery
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Patient Scar Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cleansing level of colon
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Detected lesion number during colonoscopy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Erythema resolution
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Proinflammatory interleukin concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: major bleeding episode
Endpoint domain: Adverse events/effects
Primary endpoint: Time required to obtain informed consent
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Proportion of women who agree to HIV testing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of women identified as HIV infected during labor who accept ARV prophylaxis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neonatal ICU admission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Progression-free survival rate (PFSR)
Endpoint domain: Mortality/survival
Primary endpoint: Prevalence of leukotrichia within vitilignous areas
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Acid base status measured by pH, BEecf and Bicarbonate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: non-fatal MI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: repeat re-vascularization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Visual analysis of pulmonary lobes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: plasma level of TMAO
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Efficacy of Atomoxetine in ADHD adults
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Student comfort and confidence in performing the pediatric physical exam
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Proportion of subjects rating bitterness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: changes in automated static visual field decibel values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Residual lens lysozyme
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Disabilities arm shoulder and hand score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Diagnosis of colorectal cancer or advanced adenomas
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Pharmacodynamic endpoints (PD endpoints)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Knee osteoarthritis outcome score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: The Western Ontario and McMaster Universities Osteoarthritis Index
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Short Form 36 Health Survey Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Percent subjects who reach PASI 75
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Adherence rate greater than or equal to 95%
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Complete common bile duct accessing rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change of Number of Hospital Re-admissions
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Change of Self-management Success
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change of nondependent / dependent tidal variation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Orotracheal intubation rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Patient Voiding Diary
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Adverse Events reported cumulatively throughout study
Endpoint domain: Adverse events/effects
Primary endpoint: Efficacy of Dopamine Versus Norepinephrine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Safety of Dopamine Versus Norepinephrine
Endpoint domain: Adverse events/effects
Primary endpoint: Tetranectin expression measure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Potential for Reversibility of Pharmacodynamic Effects on Coagulation Parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change From Baseline in Potential for Reversibility of Pharmacodynamic Effects on Platelet Function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Modified Sulcus Bleeding Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Probing Depth (PD, in millimeters)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gingival margin level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Central Visual Field Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: High sensitivity CRP (hsCRP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum fibrinogen
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ferritin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete blood count data (CBC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient Self-advocacy for Hand Hygiene
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Area under the serum IDeg concentration time curve after single dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum observed serum IDeg concentration after single dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma liraglutide concentration time curve after single dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum observed plasma liraglutide concentration after single dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of pathogens causing lower respiratory tract infections
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Response as Assessed by the Oral Mucositis Rating Scale (OMRS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Avoidance of allogeneic blood products transfusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Average stool consistency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: biochemical markers of fertility/infertility
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Mean changes in time scores of the obstacle subtask
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of life years gained
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Incidence of avoided endotracheal intubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: CAC scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in emotion relating to medicines
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Effect of spasticity on daily life
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: NFkB signaling activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Participants With at Least 1 Point Reduction in Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Interleukin-8 (IL-8) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Diagnostic accuracy of the basophil activation test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative Q value
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of preventive oral health care visits per patient
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Patient access to AYA specific supportive care
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Patient's/health care professional's satisfaction with the AYA at USC program
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Closure of the corneal wound
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Elapsed time from clamp release to hemostasis at the suture line
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: All adverse events occurring from the surgical procedure to Week 12
Endpoint domain: Adverse events/effects
Primary endpoint: Peripheral Blood Immunograms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: percentage of hard time living
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: maximum total lisdexamfetamine dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stability of buffer transfer medium
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidences of adverse events and adverse drug reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of Postoperative Urinary Retention
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Maximum steady state plasma concentration (Cmax,ss)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PrEP medication adherence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Absence of bacterial contamination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Improved work productivity
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: change in serotonin-transporter binding potential
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in unmet dementia-related needs
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Successful completion of the test
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Number of Participants and Prescribers Providing Correct Responses
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Incidence of positivity for fungal specific pathogens
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Number of patients who discontinue from study initiation to end of observation/follow up
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Symptoms reduction time frame
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NT-proBNP 1-24h
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: 48-hour ambulatory blood pressure monitoring (ABPM)- 1 mean BP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: echocardiographic examinations - median values of Ejection Fraction (EF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Combined death and disability
Endpoint domain: Mortality/survival
Primary endpoint: Level of Pain/Heat in the Lower Extremities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response rate (clinical and radiological)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of goose bump impressions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean area of goose bump impressions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Spatial spread of axon-reflex pilomotor response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Steady-state Pharmacokinetics of Mycophenolic Acid and Mycophenolic Acid Glucuronide
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Who Achieved Lactate Dehydrogenase (LDH) Less Than or Equal to (≤) 1.5* ULN From Baseline to Week 26
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in Montgomery-Åsberg Depression Rating Scale (MADRS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Lung imaging absorption improvement time after treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to improve cough symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: The time to disappear rhonchus in the lungs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Time to reach maximum concentration (tmax) of Ibrutinib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration-Time Curve From Time Zero to Infinite Time (AUC [0-infinity]) of Ibrutinib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Experiencing New Onset Chronic Medical Conditions (NOCMCs)
Endpoint domain: Adverse events/effects
Primary endpoint: local control (LC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Immune biomarkers level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Metastatic mediators level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: P2X7R-inflammasome activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Adolescent Drug Use Consequences
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: DSM-IV Substance Use Diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients whose measured AUC falls within or outside the therapeutic MPA target range
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients achieving one or more therapeutic level AUC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients with malignant tumors and pre-malignant lesions of the head & neck
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Occurrence of treatment-emergent SAEs
Endpoint domain: Adverse events/effects
Primary endpoint: pain free at 2 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in tumor biology
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in Attitudes toward Evidence-Based Practices
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Subjective Norms
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Change in Perceived Behavioral Control
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Prevalence of Plavix resistance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Disease modifying therapy utilization
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Area Under the Curve From Time 0 to Infinity (AUC0-inf) of Plasma Islatravir (ISL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Concentration (Cmax) of Plasma ISL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Apparent Terminal Half-life (t1/2) of Plasma ISL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of venepuncture attempts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Incidence of grade III/IV diarrhoea
Endpoint domain: Adverse events/effects
Primary endpoint: Quality of Life (QOL) difference measured by EORTC QLQ-C30
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Quality of Life (QOL) difference measured by EORTC QLQ-H&N 35
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Xerostomia score difference
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of R0 resection or pathologically confirmed CR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Feasibility of administering hypnotic closed loop
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum tolerated dose (MTD) of temsirolimus
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of toxic death
Endpoint domain: Mortality/survival
Primary endpoint: Patient-perceived pain
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Rates of completion of mentor-mentee calls
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Withdrawal Rate
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Acceptability of iPeer2Peer SCD intervention
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Cormack Lehane grade with cricoid pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Successful completion of modified ATT regimen
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: significant leakage between QuadraLite® mask and facial mask
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma levels of DRV
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Atrial Fibrillation (AF) recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number and type of genetic variants
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urges to Smoke
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MEMS adherence
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Postpartum health
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change of limits of stability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of center of gravity control
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Successful Sedation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in serum cholesterol and triglyceride levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Prognostic accuracy of the algorithm at predicting sepsis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Number of Participants Who Successfully Completed the Study Imaging Component
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Short Form-36 Score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in depressivity
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Oxygen saturation decline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in muscle oxygenation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post-procedure revascularization success
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes